Kim Kelderman - 19 Nov 2021 Form 4 Insider Report for BIO-TECHNE Corp (TECH)

Role
Pres. Diagnostics & Genom
Signature
/s/ Brenda S. Furlow as Attorney-in-Fact for KimKelderman pursuant to Power of Attorney previously filed.
Issuer symbol
TECH
Transactions as of
19 Nov 2021
Net transactions value
-$177,299
Form type
4
Filing time
23 Nov 2021, 19:02:07 UTC
Previous filing
24 Sep 2021
Next filing
10 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TECH Common Stock Options Exercise $75,390 +500 $150.78 500 19 Nov 2021 Direct
transaction TECH Common Stock Sale $50,376 -100 -20% $503.76* 400 19 Nov 2021 Direct
transaction TECH Common Stock Sale $202,313 -400 -100% $505.78* 0 19 Nov 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TECH Stock Option (Right to Buy) Options Exercise $0 -500 -19% $0.000000 2,152 19 Nov 2021 Common Stock 500 $150.78 Direct F2
holding TECH Stock Option (Right to Buy) 7,348 19 Nov 2021 Common Stock 7,348 $150.78 Direct F3
holding TECH Stock Option (Right to Buy) 12,044 19 Nov 2021 Common Stock 12,044 $177.32 Direct F4
holding TECH Stock Option (Right to Buy) 9,033 19 Nov 2021 Common Stock 9,033 $177.32 Direct F5
holding TECH Restricted Stock Units 2,363 19 Nov 2021 Common Stock 2,363 Direct F6, F7
holding TECH Stock Option (Right to Buy) 11,961 19 Nov 2021 Common Stock 11,961 $190.41 Direct F7
holding TECH Stock Option (Right to Buy) 15,948 19 Nov 2021 Common Stock 15,948 $190.41 Direct F8
holding TECH Restricted Stock Units 2,015 19 Nov 2021 Common Stock 2,015 Direct F6, F9
holding TECH Stock Option (Right to Buy) 8,991 19 Nov 2021 Common Stock 8,991 $267.87 Direct F9
holding TECH Stock Option (Right to Buy) 11,988 19 Nov 2021 Common Stock 11,988 $267.87 Direct F10
holding TECH Stock Option (Right to Buy) 8,325 19 Nov 2021 Common Stock 8,325 $267.87 Direct F11
holding TECH Stock Option (Right to Buy) 8,325 19 Nov 2021 Common Stock 8,325 $267.87 Direct F12
holding TECH Restricted Stock Units 1,245 19 Nov 2021 Common Stock 1,245 Direct F6, F13
holding TECH Stock Option (Right to Buy) 4,864 19 Nov 2021 Common Stock 4,864 $481.82 Direct F13
holding TECH Stock Option (Right to Buy) 6,486 19 Nov 2021 Common stock 6,486 $481.82 Direct F14
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $505.62 to $506.17, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 Options to purchase 663 shares vest on each of 5/1/2019, 5/1/2020, 5/1/2021 and 5/1/2022.
F3 Options to purchase 1,837 shares vest on each of 5/1/2019, 5/1/2020, 5/1/2021 and 5/1/2022.
F4 Options to purchase 3,011 shares vest on each of 8/8/2019, 8/8/2020, 8/8/2021 and 8/8/2022.
F5 Fully exercisable.
F6 Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
F7 Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
F8 Options to purchase 3,987 shares vest on each of 8/7/2020, 8/7/2021, 8/7/2022 and 8/7/2023.
F9 Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
F10 Options to purchase 2,997 shares vest on each of 8/5/2021, 8/5/2022, 8/5/2023 and 8/5/2024.
F11 Options to purchase 2,775 shares vest on each of 8/5/2021, 8/5/2022 and 8/5/2023.
F12 Vests in full on the date performance of certain product revenue goals during the period of fiscal 2021-2023 is certified by the Administrator, in no event earlier than 8/5/2021.
F13 Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
F14 Options to purchase 1,621 shares vest on each of 8/6/2022 and 8/6/2023 and options to purchase 1,622 shares vest on each of 8/6/2024 and 8/6/2025.